论文部分内容阅读
目的评价比较贝伐单抗联合化疗方案FOLFIRI(伊立替康、氟尿嘧啶、亚叶酸钙)和FOLFOX(奥沙利铂、氟尿嘧啶、亚叶酸钙)治疗转移性结直肠癌疗效及安全性。方法回顾性总结我院2012年1月~2013年3月期间分别给予贝伐单抗联合FOLFIRI方案(A组,19例)和贝伐单抗联合FOLFOX方案(B组,23例)接受化疗后的有效率、不良反应、治疗前后肿瘤标志物的变化。结果 A组和B组的有效率分别为26.3%和39.1%,A组和B组的疾病控制率分别为84.2%和82.6%。所有患者治疗前后肿瘤标志物浓度无明显变化(P>0.05),A组和B组比较差异不具有统计学意义(P>0.05)。两组不良反应大部分为Ⅰ~Ⅱ级,无严重不良反应,且差异无统计学意义(P>0.05)。结论贝伐单抗联合FOLFIRI和FOLFOX两种化疗方案对于转移性结直肠癌治疗具有良好的效果,联合FOLFOX效果更佳。患者不良反应不尽相同,均为轻到中度,患者能够耐受。
Objective To evaluate the efficacy and safety of bevacizumab in combination with chemotherapy regimen FOLFIRI (irinotecan, fluorouracil, leucovorin) and FOLFOX (oxaliplatin, fluorouracil, leucovorin) in the treatment of metastatic colorectal cancer. Methods A retrospective review was conducted from January 2012 to March 2013 in our hospital after treatment with bevacizumab plus FOLFIRI (group A, n = 19) and bevacizumab plus FOLFOX (group B, n = 23) The efficiency, adverse reactions, changes in tumor markers before and after treatment. Results The effective rates of group A and group B were 26.3% and 39.1%, respectively. The disease control rates of group A and group B were 84.2% and 82.6% respectively. All patients had no significant changes in tumor marker concentrations before and after treatment (P> 0.05). There was no significant difference between group A and group B (P> 0.05). Most of the two groups of adverse reactions were grade Ⅰ ~ Ⅱ, no serious adverse reactions, and the difference was not statistically significant (P> 0.05). Conclusion Bevacizumab combined with FOLFIRI and FOLFOX two chemotherapy for the treatment of metastatic colorectal cancer has good results, combined with FOLFOX better. Patients with adverse reactions vary, are mild to moderate, patients can tolerate.